Challenges and Opportunities in Developing Neurologic Therapies - Page 7

Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356-61. No authors given. NeuroNEXT: accelerating drug development in neurology. Lancet Neurol. 2012;11(2):119. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6(7):521-32. Preskorn S. CNS Drug Development: Part III: Future Directions. J Psychiatric Pract. 2011;17(1):49-52. Pritchard JF. Risk in CNS drug discovery: focus on treatment of Alzheimer’s disease. BMC Neuroscience. 2008;9(Suppl 3):S1. Richards D. Drug development and regulation. Medicine. 2008;36:369-76. Shineman DW, Fillit HM. Meeting the unique challenges of drug discovery for neurodegenerative diseases. BMC Neurol. 2009;9(Suppl 1):11. Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol. 2009;9(Suppl 1):S2. World Health Organization. Neurological disorders: Public health challenges. 2006. Available at: http://www.who.int/mental_health/neurology/neurodiso/en/. Accessed on 31 January 2012.